Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on December 14, 2020, covering events occurring on December 11, 2020, and December 13, 2020. The Company is a Delaware corporation with its principal executive offices in New York, NY, and its common stock trades on the Nasdaq Capital Market under the symbol "SLS."
Key Financial Metrics and Capital Events
- Registered Direct Offering: The Company entered into a Share Purchase Agreement to sell 2,320,000 shares of Common Stock at $7.00 per share, generating gross proceeds of approximately $16.2 million.
- Placement Agent Fees: The Company engaged Maxim Group LLC as the exclusive lead placement agent for a fee of 6.0% of gross proceeds, plus reimbursement of out-of-pocket expenses and legal fees up to $50,000.
- Warrant Exercises: Between October 1, 2020, and December 11, 2020, warrants to purchase 2,412,632 shares were exercised at a weighted average price of $3.35 per share, yielding approximately $8.1 million in proceeds.
- Outstanding Warrants: As of December 11, 2020, warrants to purchase 1,451,594 shares remained outstanding with a weighted average exercise price of $26.91.
Note: This filing does not provide specific data on revenue, net profit, operating margins, total debt, or liquidity positions beyond the proceeds from the capital events described above.
Material Changes and Agreements
The primary material change is the execution of a Share Purchase Agreement for a registered direct offering. The Company agreed to restrictions on the issuance and sale of Common Stock or Common Stock Equivalents for a 30-day period following the closing of the Offering. The Offering was expected to close on or about December 16, 2020, subject to customary closing conditions.
Outlook, Risks, and Contingencies
The filing indicates the Offering is subject to customary closing conditions. The Company has entered into customary representations, warranties, and indemnification obligations with the Investors and the Placement Agent. No specific forward-looking guidance regarding future revenue or operational milestones is provided in this specific report.
Key Facts for Investor Verification
- Verify the final closing date of the registered direct offering and the net proceeds received after deducting the 6.0% placement fee and offering expenses.
- Confirm the dilution impact of the 2,320,000 new shares issued at $7.00 per share.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and the 30-day lock-up restrictions.
- Monitor the status of the remaining 1,451,594 outstanding warrants with a high weighted average exercise price of $26.91.